Capricor Therapeutics, Inc.
CAPR
|
$5.01
-0.79%
-0.8%
350K
|
Health Technology
(0.0% 1d) (-26.3% 1m) (22.0% 1y) (0.0% 2d) (0.0% 3d) (-13.8% 7d) (238.36% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 157,829,890
http://www.capricor.com
Sec Filling | Patents | 16 employees
(US) Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
duchenne dmd treatment
add to watch list Paper trade email alert is off
Press-releases
Capricor Therapeutics to Present at Upcoming Investor Conferences
Published: 2024-03-21 (Crawled : 13:00) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: 1.02%
H: 1.73%
C: -0.58%
therapeutics
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: 5.35%
H: 1.15%
C: -0.67%
conference association therapeutics
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: 5.48%
H: 5.87%
C: 3.05%
year update therapeutics financial results
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
Published: 2024-02-27 (Crawled : 13:30) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: 2.53%
H: 13.6%
C: 6.9%
cap-1002 fda meeting commercial therapeutics duchenne
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
Published: 2024-02-22 (Crawled : 13:30) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: 1.55%
H: 1.02%
C: -1.02%
year update therapeutics financial results
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
Published: 2024-02-20 (Crawled : 13:30) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: 1.39%
H: 5.19%
C: 4.92%
cap-1002 commercialization therapeutics
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Published: 2024-01-24 (Crawled : 14:30) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: 2.18%
H: 6.4%
C: -3.32%
vaccine sars-cov-2 collaboration trial therapeutics
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
Published: 2023-12-11 (Crawled : 14:00) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: 0.54%
H: 5.39%
C: -2.7%
cap-1002 continuation trial therapeutics duchenne
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-14 (Crawled : 21:00) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: -0.33%
H: 13.0%
C: 7.0%
update therapeutics financial results
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K
|
Health Technology
|
| O: -0.53%
H: 1.41%
C: 0.7%
update therapeutics financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
BCDA | $0.377 -1.4% 97K
|
Health Technology
|
22:00
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10